SQZ Biotech, Inc. logo

SQZ Biotech, Inc.

SQZ Biotech (spun out of MIT) is cell engineering startup developing novel methods to engineer cell function and harness the power of a patients own cells to combat disease more effectively across a broad range of indications.

SQZ maintains the exclusive worldwide license from the Massachusetts Institute of Technology for CellSqueeze for any application. SQZ technology was discovered, almost accidentally, at Robert Langers lab at MIT, that when you squeeze a cell the right way it will disrupt the surface, opening doors to introduce molecules inside the cell.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://sqzbiotech.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
134 Coolidge Avenue, MA, 02472
Watertown
United States
Email
Contact Number
+1 617-758-8672

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sqz-biotechnologies” connections=”true” suffix=””]

SQZ Biotech proprietary CellSqueeze technology platform, squeezes cells to allow material to pass across the temporarily-disrupted membrane. In cancer, technology enables to insert tumor related antigens into cells extracted from patients and then put them back in the patient. SQZ is working on APC (antigen presenting cell) designed to deliver antigens and thereby prime a patients killer T cells to attack HPV-positive tumors, with the first clinical results expected by 2019 end.

In Dec 2015, SQZ Biotech signed a deal with Roche to develop a cell therapy platform that would empower patients own immune cells to fight a broad range of cancers. The deal leverages SQZs pioneering technology to engineer B cells as a therapeutic platform for oncology. The agreement provides for over $500M in upfront and potential clinical, regulatory and sales milestone-based payments for advancement of all products across all planned indications, in addition to royalties on potential future products.

In Aug 2018, SQZ raised $78 Mn in Series C oversubscribed round, bringing in new investors including Illumina Ventures, Invus, Viva Ventures Biotech Group, Everblue and Orient Life along with existing backers including Bridger Healthcare Partners, Global Health Science Fund, GV, The JDRF T1D Fund, NanoDimension and Polaris.

In 2014, SQZ raised $1 Mn in seed funding from angel investors, followed the next year in June 2015 a $5 Mn in series A venture funding from Polaris Partners, 20/20 HealthCare Partners and two other investors.